H.C. Wainwright lowered the firm’s price target on Karyopharm (KPTI) to $7 from $56 and keeps a Buy rating on the shares. The firm updated its model for the reverse stock split.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm trading halted, news pending
- Karyopharm implementing 1-for-15 reverse stock split
- Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
- Karyopharm’s Earnings Call: Growth Amid Financial Challenges
- Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue